Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21991

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Transurethral Resection of Bladder Tumor; Procedure · Biological · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 182
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 146 more

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Glendale, California • Coral Springs, Florida • Jeffersonville, Indiana + 11 more

Conditions: Orthopaedic Fractures, Socioeconomic Factors
Interventions: Social Work support; Other
Lead sponsor: Sheila Sprague; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Geographic Atrophy, Stargardt Disease, RPE-mediated Maculopathy, Age Related Macular Degeneration
Interventions: Injection; Biological
Lead sponsor: Cellio Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Beverly Hills, California • Palo Alto, California • Sacramento, California

Conditions: Ovarian Cancer, Non-small Cell Lung Cancer
Interventions: TUB-040, Bevacizumab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 10 more

Conditions: Multiple Myeloma
Interventions: Cilta-cel, Cyclophosphamide, Induction therapy, Fludarabine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: San Francisco, California • Tampa, Florida • Iowa City, Iowa + 4 more

Conditions: Colitis, Ulcerative
Interventions: JNJ-78934804, Guselkumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 30
States / cities: Scottsdale, Arizona • Sun City, Arizona • Anaheim, California + 27 more

Conditions: Sickle Cell Disease
Interventions: Anumigilimab, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Little Rock, Arkansas • Orange, California • Hollywood, Florida + 11 more

Conditions: oGVHD, Ocular Graft Versus Host Disease
Interventions: d-MAPPS™ Ophthalmic Solution, Matching vehicle control; Biological
Lead sponsor: Regenerative Ocular Immunobiologics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Beverly Hills, California • Palm Harbor, Florida • Boston, Massachusetts

Conditions: Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
Interventions: Biospecimen Collection, Cabozantinib, Computed Tomography, Everolimus, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Sunitinib; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Neoplasms, Endometrial
Interventions: Mocertatug rezetecan, Paclitaxel, Doxorubicin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Birmingham, Alabama • Omaha, Nebraska • Sugar Land, Texas + 1 more

Conditions: Irritable Bowel Syndrome
Interventions: True avoidance diet, Sham avoidance diet; Other
Lead sponsor: IBS-80, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: North Wales, Pennsylvania • Philadelphia, Pennsylvania

Recruiting clinical trials

Filter and sort this status page

Live official records

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Trial of Social Work Services in Fracture Clinic Setting

Phase 1 Study of C.001 in Retinal Degeneration

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Study of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD)

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

IBS Skin Patch Test Food Allergy Study